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Abstract
Human papillomavirus (HPV)-associated penile lesions in men may increase the risk of HPV
transmission to their female partners. Risk factor data on HPV-associated penile lesions are
needed from regions with a high burden of cervical cancer. Visual inspection of the penis was
conducted using a colposcope at the 24-month visit among participants in a randomized controlled
trial of male circumcision in Kenya, from May 2006 to October 2007. All photos were read
independently by two observers for quality control. Penile exfoliated cells sampled from the glans/
coronal sulcus and the shaft were tested for HPV DNA using GP5+/6+ PCR and for HPV16, 18
and 31 viral loads using a real time PCR assay. Of 275 men, 151 were circumcised and 124
uncircumcised. The median age was 22 years. Circumcised men had a lower prevalence of flat
penile lesions (0.7%) versus uncircumcised (26.0%); adjusted odds ratio [OR]=0.02; 95%
confidence interval [CI]: 0.003–0.1). Compared to men who were HPV-negative, men who were
HPV DNA positive (OR=6.5; 95%CI: 2.4–17.5) or who had high HPV16/18/31 viral load
(OR=5.2; 95%CI: 1.1–24.4) had higher odds of flat penile lesions. Among men with flat penile
lesions, HPV56 (29.0%) and 16 (25.8%) were the most common types. Flat penile lesions are
much more frequent in uncircumcised men, and associated with higher prevalence of HPV and
higher viral loads. This study suggests that circumcision reduces the prevalence of HPV-
associated flat lesions and may ultimately reduce male to female HPV transmission.
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Human papillomavirus (HPV) infection is the central cause of cervical cancer in women and
plays an important role in other anogenital cancers in men and women1–4. Interventions that
reduce HPV-associated penile lesions could be important to both men and women, because
HPV-associated penile lesions may increase HPV transmission to their sexual partners5.
Flat penile lesions are flat or slightly elevated, well demarcated, acetowhite lesions in which
a capillary pattern can be observed6. They are commonly found among male partners of
women with cervical intraepithelial neoplasia (CIN), but often go unnoticed without the
application of acetic acid6–8. Positive associations have been found between flat penile
lesions, lack of condom use, HPV positivity and high HPV viral load6,9,10. More data,
however are needed to determine the type-specific distribution of HPV infection and
whether other risk factors are associated with penile lesions. Other common penile lesions,
including papular lesions and pearly penile papules, have not been associated with HPV
infection6,11. While circumcision has been previously associated with a lower point-
prevalence of HPV infection12–15 and a decreased incidence of high-risk HPV16, it is
unknown whether circumcision reduces the prevalence of flat penile lesions. It is also
unclear whether risk factors other than HPV infection differ between flat penile lesions,
papular lesions and pearly penile papules.
The primary aim of this study was to determine the association between male circumcision
status and HPV-associated flat penile lesions among men from Kenya. We also sought to
investigate risk factors for penile lesions, including HPV, type-specificity and viral load of
the HPV infection.
MATERIALS AND METHODS
Study Population and Enrollment
Uncircumcised men were screened between February 4, 2002 and September 6, 2005 in
Kisumu, Kenya to participate in a randomized controlled trial (RCT) of male circumcision
registered with ClinicalTrials.gov (NCT00059371)17. The primary aim of the RCT was to
determine the effectiveness of male circumcision in reducing human immunodeficiency
virus (HIV) incidence. Inclusion criteria included being uncircumcised, aged 18–24 years,
HIV seronegative, sexually active, and having blood hemoglobin ≥9.0 g/dL. Study
participants were recruited from sexually transmitted infection (STI) clinics, workplaces,
and community organizations. For men in the intervention group, circumcision was
normally performed within a few days of randomization and these men were counseled to
abstain from sexually activity for at least 30 days after surgery.
Beginning May 5, 2006, RCT participants were invited to participate in a visual inspection
examination of the penis with 3% acetic acid (VIA) at their 24-month visit. Of 1,398 men
enrolled in the RCT with a 24-month visit after May 5, 2006, 275 (20%) consented to the
VIA exam and were included in this sub-study. The study protocol was approved by the
Institutional Review Boards of the Universities of Illinois at Chicago, Manitoba, Nairobi,
and North Carolina; RTI International; and the VU University Medical Center.
Questionnaire and Specimen Collection
After undergoing informed consent, participants were administered a standardized
questionnaire on sociodemographic characteristics and sexual behavior by a trained male
interviewer at baseline and the 24-month visit17. Penile exfoliated cells were collected for
HPV DNA detection at baseline prior to circumcision and at the 24-month visit from two
anatomical sites: i) shaft and external foreskin tissue (shaft specimen) and ii) glans, coronal
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sulcus and inner foreskin tissue (glans specimen), using pre-wetted Type 3 Dacron swabs in
separate conical tubes18.
Penile cell samples were placed in individual 15-mL centrifuge tubes containing 2-mL of
0.01 mol/L Tris-HCl, 7.4 pH buffer, and processed on the day of collection at the
Universities of Nairobi, Illinois, and Manitoba (UNIM) clinic laboratory in Kisumu by
centrifugation at high speed (maximum, 3000g) for 10 minutes. Excess Tris-HCl buffer was
discarded using a Pasteur pipette, and the remaining cell pellet was resuspended in the same
volume of 0.01 mol/L Tris-HCl buffer, and vortexed. Diluted cell pellets were then frozen at
−75°C. Samples were sent using a liquid nitrogen dry shipper to the Department of
Pathology, VU University Medical Center, Amsterdam, the Netherlands, for HPV DNA
testing.
Visual Inspection Exams
After genital sampling for HPV DNA, consenting study participants were screened for
penile lesions at the 24-month visit by visual inspection aided by a colposcope for
magnification. The first visual inspection exam was conducted before the application of 3%
acetic acid. A second exam was performed 2–3 minutes after acetic acid application to
identify HPV-associated flat penile lesions. Acetic acid was applied with saturated gauze to
the penile shaft, glans, coronal sulcus, frenulum, and outer and inner foreskin tissue for
uncircumcised men.
Penile lesions were categorized as follows: i) flat lesions (flat or slightly elevated, well
demarcated, acetowhite lesions in which a capillary pattern can be seen); ii) condylomata
acuminata, or genital warts (exophytic lesions with an irregular surface); iii) papular lesions
(small exophytic papules usually located near the frenulum with a smooth surface on which
a hyperkeratinized layer could be present)6; and iv) pearly penile papules (small exophytic
papules located around the corona, presenting in 1 to 4 rows)11. The VIA exams were
performed by male medical doctors who were trained intensively by experienced medical
doctors who had performed VIA in over 500 men. Both practical experience and a manual
with multiple examples were used during this training.
The lesion type and anatomical site were recorded on standardized forms. Digital
photographs were taken of ventral and dorsal sides of the glans/coronal sulcus with penile
foreskin retracted for uncircumcised men before and after acetic acid application. All
photographs were double read in Amsterdam without knowing HPV data, and in case of
discrepancies (<10%), a consensus diagnosis was made after discussing the findings with the
medical doctors who performed the VIA exams.
HPV DNA, HPV Viral Load and STI Testing
DNA was isolated from penile exfoliated cell samples using NucleoSpin 96 Tissue kit
(Macherey-Nagel, Germany) and a Microlab Star robotic system (Hamilton, Germany).
Presence of human DNA was evaluated by β-globin specific PCR, followed by agarose gel
electrophoresis. HPV positivity was assessed by GP5+/6+ PCR followed by hybridisation of
PCR products using an enzyme immunoassay readout with two HPV oligoprobe cocktails
that, together, detect 44 HPV types (high-risk: HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 66, 68; low-risk: HPV6, 11, 26, 30, 32, 34, 40, 42, 43, 44, 53, 54, 55, 57, 61, 64, 67, 69,
70, 71, 72, 73, 81, 82, 83, 84, cand85, 86, cand89, JC9710). Subsequent HPV genotyping
was performed by reverse line blot (RLB) hybridisation of PCR products19,20. Primers and
probe sequences, as well as cycling and staining conditions have been detailed
previously19,20. HPV16, 18 and 31 viral loads were subsequently determined using a real
time PCR assay and LightCycler instrument (Roche Diagnostics, Basel, Switzerland)21.
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High HPV DNA viral load was defined as positive when HPV16, 18 or 31 specimen viral
load was >250 copies per scrape in either glans or shaft specimens7. All other specimens
containing HPV16, 18 or 31 DNA were considered to have low HPV16/18/31 viral load.
HPV types detected by enzyme immunoassay but not by RLB genotyping were designated
as HPVX, indicating a type, sub-type or variant not detectable with probes used for RLB
hybridization. HPV infections with multiple HPV types were considered high-risk if ≥1
high-risk HPV type was detected. Men with HPVX infections were excluded from high and
low-risk HPV categorizations unless a high-risk HPV type was detected.
Urine samples were tested in the UNIM laboratory in Kisumu, and at the Department of
Medical Microbiology laboratory, University of Nairobi in Nairobi, for N. gonorrhoeae and
C. trachomatis infections by PCR-based methods (Roche Diagnostics, Basel, Switzerland).
Serum specimens were tested for herpes simplex virus type 2 (HSV-2) antibody (Kalon
Biological Ltd, Aldershot, United Kingdom) and for HIV antibody using two rapid tests
(Determine, Abbott Diagnostic Division, Hoofddorp, Netherlands; and Unigold, Trinity
Biotech, Wicklow, Ireland), confirmed by double ELISA (Adaltis Inc, Montreal, Canada;
Trinity Biotech, Wicklow, Ireland) at the University of Nairobi.
Statistical Methods
Pearson’s χ2 and Fisher’s exact tests were used to assess differences in baseline risk factors
between men in the VIA sub-study and all other RCT participants. An adjusted odds ratio
(OR) and corresponding 95% confidence interval (CI) measuring the association between
flat penile lesions and male circumcision status was estimated via a multivariate logistic
regression model adjusted for age and baseline variables significantly associated with
participation in the VIA sub-study. Multivariate logistic regression models adjusted for age
and male circumcision status were used to estimate ORs for flat penile lesions and other
potential risk factors assessed at the 24-month visit. Analyses were repeated for papular
lesions and pearly penile papule outcomes. Due to the limited number of condyloma
acuminata diagnosed among the VIA participants (n=2), risk factor analyses could not
conducted for this lesion type.
Circumcision status in this analysis was defined as actual circumcision status at the 24-
month visit. Of 151 circumcised men who consented to VIA exams, 8 (5.3%) were
originally assigned to the control arm but crossed over before the 24-month visit, and were
subsequently circumcised. Results were similar with their exclusion from analyses (data not
shown). β-globin positivity was 86.2% in the glans and 73.8% in the shaft specimens among
circumcised men and 89.2% in the glans and 73.3% in the shaft among uncircumcised men.
The effect of male circumcision on penile lesions and HPV type prevalence results did not
differ substantially when analyses were restricted to β-globin positive samples, and thus
reported analyses utilized HPV DNA data from all penile exfoliated cell specimens
regardless of β-globin positivity.
RESULTS
At baseline, men who participated in the VIA exam (N=275) were more likely to live with
their female sexual partner (p=0.01) and have ≥2 sex partners during the past 12 months
(p<0.001), compared to all other RCT participants (N=2,509) (Table 1). All other baseline
risk factors assessed were similar between men who did and did not participate in the VIA
study.
Of the 275 participants, 151 (54.9%) men were circumcised and 124 (45.1%) uncircumcised
at the 24-month visit. Baseline risk factors assessed, including HPV DNA positivity
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(p=0.88), condom use (p=0.81) and the number of sexual partners within the last year
(p=0.54), did not differ between the circumcised and uncircumcised groups (Table 2). The
median age of all participants at the 24-month visit was 22 years (range 20–26). One
participant was HIV seropositive (0.36%), while 28 were HSV-2 seropositive (14.6%) at the
24-month visit. Less than 2% of men had laboratory-diagnosed N. gonorrhoeae or C.
trachomatis infections, or reported having had a sexually transmitted disease within the last
6 months. The median number of female sexual partners in the previous 12 months was 2
women (range 0–14). No men reported having a male sexual partner in their lifetime.
Prevalence of Penile Lesions
A total of 33 (12.0%) men had flat penile lesions detected after acetic acid application. The
foreskin (or foreskin remnant among circumcised men) was the most common site for flat
lesions (9.9%), followed by the frenulum (3.3%) and glans (2.6%). No flat lesions were
detected on the penile shaft of any participant. Two uncircumcised participants were
diagnosed with genital warts. Papular lesions (n=133; 48.4%) and pearly penile papules
(n=187; 68.0%) were commonly present in both circumcised and uncircumcised men.
Association of Male Circumcision and Penile Lesions
Circumcised men were much less likely than uncircumcised men to have flat lesions (0.7%
versus 26.0%, crude OR=0.02; 95%CI: 0.003–0.1). The strong association between
circumcision and flat penile lesions remained after controlling for age, baseline marital
status and the number of female sexual partners in the 12 months prior to enrolling in the
RCT (OR=0.02; 95%CI: 0.003–0.1) (Table 3). The adjusted OR was similar when the
analysis was restricted β-globin positive samples (OR=0.02; 95%CI: 0.003–0.02).
Circumcised men were more likely to have papular lesions (OR=3.0; 95%CI: 1.8–5.1 vs.
uncircumcised) after controlling for age, baseline marital status and partners in the past 12
months. Male circumcision was also positively associated with pearly penile papules in the
adjusted model (OR=1.9; 95%CI: 1.1–3.2) (Table 3).
Risk Factors for Flat Penile Lesions Other than Male Circumcision
Flat penile lesions were more common among HPV-positive men (21.2%, vs. 4.6% in HPV-
negative men; OR=6.5; 95%CI: 2.4–17.5). A strong association was also found between flat
lesions and men with high-risk HPV types vs. men who were HPV-negative (OR=8.3;
95%CI: 3.0–22.8). Both HPV DNA detected in the glans (OR=5.4; 95%CI: 2.1–14.0) and
shaft (OR=5.1; 95%CI: 2.1–12.9) were strongly associated with flat penile lesions (Table 4).
Compared to men who were HPV-negative, participants with high HPV16/18/31 viral load
were more likely to have flat penile lesions (OR=5.2; 95%CI: 1.1–24.4) (Table 4). Even
men with low viral load were more likely to have flat lesions compared to HPV-negative
men (OR=4.3; 95%CI: 1.0–18.1). Compared to men who were HPV-negative, a particularly
strong association was found between high HPV16/18/31 viral load in the glans and the
presence of flat penile lesions (OR=8.0; 95%CI: 1.5–41.8), with a weaker association found
in the shaft (OR=3.8; 95%CI: 0.5–29.4) (data not shown).
Other risk factors assessed including education, condom use in the last 6 months, number of
female sexual partners in the past 12 months and years of sexual activity were not
significantly associated with flat lesion prevalence (Table 4).
Risk Factors for Papular Lesions and Pearly Penile Papules
HPV DNA positivity was not associated with papular lesions (OR=0.8, 95%CI: 0.5–1.3 vs.
HPV-negative), nor with pearly penile papules (OR=0.8; 95%CI: 0.5–1.4), after controlling
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for age and circumcision status (Table 4). Papular lesions and pearly penile papules were
also not associated with other risk factors assessed such as HPV16/18/31 viral load,
education, and the number of female sexual partners in the past 12 months.
HPV type distribution among men with and without flat penile lesions
Among men with flat penile lesions, 30 individual HPV types were detected at the 24-month
visit, with high-risk HPV56 (29.0%) and 16 (25.8%) the most common types within single
or multiple HPV infections (Figure 1). The next three most common HPV types were high-
risk HPV52 (19.4%), 35 (12.9%) and 66 (12.9%). All other HPV types detected (n=25) had
an HPV prevalence of less than 10%, including HPV18 (9.7%) and HPV6 (9.7%). HPV11
was not detected among any participant with flat penile lesions. At baseline, HPV
prevalence among men with flat penile lesions was 53.3%. Of the 30 men with flat penile
lesions who had HPV DNA data available from both the baseline and 24-month visit, 27
(90.0%) were HPV positive at one or more visit (data not shown).
A total of 40 HPV types were detected among men without flat penile lesions, with HPV16
the most common type (9.4%) within single or multiple infections. The next four most
common types were HPV45 (3.9%), HPV66 (3.9%), HPV51 (3.4%), and HPV58 (3.4%).
HPVX infections were found in 4.4% of men without flat lesions. All other HPV types
detected (n=35) were found in ≤3% of participants, including HPV18 (2.6%), HPV6 (2.1%)
and HPV11 (1.3%).
The prevalences of the 5 most common individual HPV types among men with flat penile
lesions were all higher than the corresponding HPV prevalences among men without flat
penile lesions (Figure 1). Multiple HPV types (defined as having ≥2 different high-risk or
low-risk types) were more common among men with versus without flat penile lesions
(67.7% vs. 19.6%, p<0.001).
DISCUSSION
Male circumcision was strongly associated with reduced odds of flat penile lesions. Men
with HPV DNA detected had higher odds of flat penile lesions than men who were HPV-
negative. High-risk HPV infection and high HPV16/18/31 viral load in the glans were
particularly strong risk factors for flat penile lesions.
The prevalence of flat penile lesions among uncircumcised men in our study population
(26%) was higher than that found among uncircumcised participants in a study (17%) of
men in the Netherlands who self-reported no STI infections7. The prevalence of flat lesions
among circumcised men in both studies was <1%. Higher flat lesion prevalence among
uncircumcised men in our study could be due to the younger age of our study population.
Our results are consistent with previous studies that found associations between flat penile
lesions and HPV using PCR or in situ hybridization methods6,22. HPV prevalence among
men with flat lesions in our study (77%) was similar to that observed among 175 male
sexual partners of women with CIN from the Netherlands (72%)6. Flat penile lesions were
strongly associated with high-risk HPV infection and high HPV16/18/31 viral loads,
especially in the glans, supporting findings from previous studies that HPV might play a role
in their etiology6,22–24. These lesions could also be a useful parameter for evaluating
efficacy of prophylactic HPV16/18 vaccines, given their common occurrence and strong
associations with high-risk HPV and HPV16/18/31 viral loads. Due to their strong
association with high HPV viral load, flat penile lesions may also increase transmission
between sexual partners. Future studies on male-to-female HPV transmission are needed to
confirm this hypothesis. Condom use was associated with both flat penile lesion regression
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in a previous RCT of 100 male partners of women with CIN in the Netherlands,9 and
prevalence of flat penile lesions in this study, although our results were not statistically
significant.
Although the relationship between genital warts and HPV has been well established, the
observed prevalence of genital warts was too low to examine risk factors. The low
prevalence of genital warts (1%) is in agreement with our study population’s low prevalence
of HPV6 (3%) and 11 (1%), the types which are commonly found in genital warts. The low
prevalence of genital warts is comparable with prevalence data from other studies conducted
in Africa, South America and Europe6,8,25,26, especially among male partners of women
without known HPV infection (i.e. 0–6%)5.
Circumcision was associated with increased prevalence of papular lesions and pearly penile
papules. Papular lesions and pearly penile papules are likely not sexually transmitted and
were not associated with HPV infection in previous reports6,11,27. The association found
between circumcision and papular lesions and pearly penile papules might be due to small
mechanical traumas during intercourse or a tissue reaction following the circumcision
procedure28. Alternatively, increased keratinization as a consequence of circumcision might
lead to better visibility of papular lesions and pearly penile papules.
While previous studies have investigated HPV infection among men in Africa29,30 to our
knowledge, this is the first to investigate multiple risk factors for HPV-associated flat penile
lesions among men from this region. Study advantages also include the use of a sensitive
PCR assay and data on numerous potential risk factors. Additionally, all photos taken of
penile lesions were double read in Amsterdam without knowledge of HPV status to reduce
misclassification of penile lesions.
A study limitation is that penile lesions were diagnosed by colposcopy, and lesion diagnosis
could have been misclassified due to observational bias. Acetic acid staining is not restricted
to HPV-associated flat penile lesions. Other inflammatory conditions and traumatic micro-
abrasions may react to the acetic acid test, but a different appearance and the absence of
punctuation help to differentiate these features from true HPV-associated flat penile lesions.
Penile lesions were also not directly swabbed for HPV DNA and taking biopsies of
ascertained lesions was considered too invasive for this study population, in the context of
an RCT. Therefore, another study limitation is that HPV infection was not detected directly
from the lesion, and histological diagnosis of penile lesions was not possible. Previous
reports of flat penile lesions indicate that these lesions usually represent hyperplasia or low
grade penile intraepithelial neoplasia, although a minority of lesions may be high
grade5,6,8,22,27.
Only three HPV types were assessed for HPV DNA viral load in this study. Men categorized
as having low HPV16/18/31 viral load may have had high viral loads for HPV types not
assessed. Our sample was too small to restrict analyses to men with single HPV type
infections. Additionally, viral load analyses were not normalized to cell equivalents. This
may have contributed to variability in viral load assessment and to decreased specificity in
categorizing specimens. Thus, viral load analyses should be interpreted with caution. Data
on the baseline prevalence of flat penile lesions in this population were also not available,
and thus limiting our analyses to cross-sectional associations.
While selection bias appeared to be minimal when comparing the baseline characteristics of
study participants to other men in the RCT, our findings should be interpreted with caution
as this was a relatively small subset of men from the RCT. Participation was likely low in
this sub-study because it was started relatively late, did not originally offer compensation
unlike many other trial activities and required an additional exam at the end of the final, 24-
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month visit in which photographs were taken. The prevalence of STIs other than HPV and
HSV-2 infections was also low in our study population, and hence important associations
between penile lesions and other STIs might have been missed. Additionally, our results
may not be generalizable to other African cohorts due to the low prevalence of HIV (<1%)
among our participants at the 24-month visit.
Male circumcision was strongly associated with reduced odds of flat penile lesions. Because
flat penile lesions were also strongly associated with high-risk HPV infection and higher
HPV16/18/31 viral load, circumcision may also reduce male-to-female high-risk HPV
transmission31,32. Male circumcision has been found to be an acceptable and effective
intervention to reduce HIV incidence among African men17,33–35. Since prophylactic HPV
vaccines may not be readily available to men in many less developed countries and current
HPV vaccines do not include all high-risk HPV types, circumcision may also provide a
useful intervention to prevent HPV-associated penile lesions and ultimately invasive
cervical cancer in developing countries.
Novelty and impact of the paper
To our knowledge, these data are the first to show that male circumcision reduces the
prevalence of HPV-associated flat penile lesions. Given that flat penile lesions were also
strongly associated with high-risk HPV infection and high HPV viral load, male






CIN cervical intraepithelial neoplasia
RCT randomized controlled trial
HIV human immunodeficiency virus
STI sexually transmitted infection
VIA visual inspection with acetic acid
UNIM Universities of Nairobi, Illinois and Manitoba
RLB reverse line blot
HSV-2 herpes simplex virus type 2
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Human papillomavirus (HPV) prevalence and 95% confidence intervals for the five most
common HPV types, HPV6, HPV11 and HPV type groupings among men with flat penile
lesions compared to men without flat penile lesions. HPV infections were considered high-
risk (HR) if ≥1 HR HPV type was detected within single or multiple infections. Low-risk
(LR) HPV infections were defined as the detection of ≥1 LR HPV type excluding co-
infections with HR types or HPVX. A multiple infection was defined as >1HR or LR HPV
type.
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Table 1
Comparison of baseline characteristics for men enrolled in the randomized controlled trial of male
circumcision who did and did not participate in the VIA sub-study
Participated in VIA sub-
study (N=275)
Did not participate in VIA
sub-study (N=2509)
Risk Factor n (%)a n (%)a p-valueb
Age (years)
    ≤19 86 (31.2) 768 (30.6) 0.39
    20–21 115 (41.8) 970 (38.7)
    ≥22 74 (26.9) 771 (30.7)
Randomization Assignment
    Uncircumcised 127 (46.2) 1266 (50.5) 0.18
    Circumcised 148 (53.8) 1243 (49.5)
HPV DNA positivityc
    Negative 124 (50.0) 980 (52.1) 0.68
    LR-positive 27 (10.9) 219 (11.6)
    HR-positive 97 (39.1) 683 (36.3)
Education
    Primary or none 100 (36.4) 847 (33.8) 0.39
    Secondary or tertiary 175 (63.6) 1662 (66.2)
Employment status
    No Income 95 (34.6) 896 (35.7) 0.70
    Income 180 (65.4) 1613 (64.3)
Condom use last 6 months
    Never 65 (25.8) 561 (26.1)
    ≤50% 101 (40.1) 800 (37.3) 0.65
    >50% 86 (34.1) 786 (36.6)
Marital Status
    Not living with partner 250 (90.9) 2367 (94.8) 0.01
    Living with partner 25 (9.1) 131 (5.2)
Age at first intercourse (years)
    8–15 132 (49.6) 1167 (48.6) 0.75
    16–21 134 (50.4) 1234 (51.4)
Partners in last 12 months
    0–1 74 (27.2) 1009 (40.6) <0.001
    ≥2 198 (72.8) 1477 (59.4)
Lifetime # of female partners
    1–4 118 (47.4) 1281 (54.7) 0.08
    5–7 63 (25.3) 533 (22.7)
    ≥8 68 (27.3) 530 (22.6)
Years of sexual activity
    0–3 78 (29.4) 788 (32.7) 0.37













Backes et al. Page 14
Participated in VIA sub-
study (N=275)
Did not participate in VIA
sub-study (N=2509)
Risk Factor n (%)a n (%)a p-valueb
    4–5 77 (29.1) 584 (24.3)
    6–7 60 (22.6) 564 (23.4)
    8–14 50 (18.9) 471 (19.6)
HSV-2-seropositive
    No 189 (71.9) 1741 (72.2) 0.90
    Yes 74 (28.1) 669 (27.8)
N. gonorrhea
    Negative 262 (97.8) 2428 (98.1) 0.65d
    Positive 6 (2.2) 48 (1.9)
C. trachomatis
    Negative 252 (94.0) 2367 (95.6) 0.22d
    Positive 16 (6.0) 108 (4.4)
Self-reported STDe
    No 253 (92.0) 2339 (93.2) 0.45d
    Yes 22 (8.0) 170 (6.8)
NOTE. VIA: visual inspection with acetic acid; HPV: human papillomavirus; HSV-2: herpes virus type 2; STD: sexually transmitted disease
a
Percentages do not include missing values
b
P-value comparing men who did and did not participate in the VIA sub-study using Pearson’s chi-square test unless otherwise noted.
c




Sexually transmitted disease (current or within the last 6 months)
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Table 2
Comparison of baseline characteristics for HIV seronegative, uncircumcised men participating in a VIA sub-






Baseline Risk Factor n (%)a n (%)a p-valueb
Age (years)
    ≤19 47 (31.3) 39 (31.5) 0.93
    20–21 62 (42.7) 53 (42.7)
    ≥22 42 (27.8) 32 (25.8)
HPV DNA positivityc
    Negative 67 (49.3) 57 (50.9) 0.88
    LR-positive 16 (11.8) 11 (9.8)
    HR-positive 53 (39.0) 44 (39.3)
Education
    Primary or none 93 (61.6) 82 (66.1) 0.44
    Secondary or tertiary 58 (38.4) 42 (33.9)
Employment status
    No Income 102 (67.5) 78 (62.9) 0.42
    Income 49 (32.5) 46 (37.1)
Condom use last 6 months
    Never 36 (26.5) 29 (25.0) 0.81
    ≤50% 52 (38.2) 49 (42.2)
    >50% 48 (35.3) 38 (32.8
Marital Status
    Not living with partner 138 (91.4) 112 (90.3) 0.83d
    Living with partner 13 (8.6) 12 (9.7)
Age at first intercourse (years)
    8–15 70 (48.6) 62 (50.8) 0.72
    16–21 74 (51.4) 60 (49.2)
Partners in last 12 months
    0–1 38 (25.7) 36 (29.0) 0.54
    ≥2 110 (74.3) 88 (71.0)
Lifetime # of female partners
    1–4 68 (50.0) 50 (44.2) 0.50
    5–7 35 (25.7) 28 (24.8)
    ≥8 33 (24.3) 35 (31.0)
Years of sexual activity
    0–3 45 (31.3) 33 (27.3) 0.26
    4–5 39 (27.1) 38 (31.4)
    6–7 28 (19.4) 32 (26.4)


















Baseline Risk Factor n (%)a n (%)a p-valueb
    8–14 32 (22.2) 18 (27.3)
HSV-2-seropositive
    No 107 (74.3) 82 (68.9) 0.33
    Yes 37 (25.7) 37 (31.1)
N. gonorrhea
    Negative 144 (98.6) 118 (96.7) 0.42d
    Positive 2 (1.4) 4 (3.2)
C. trachomatis
    Negative 139 (95.2) 113 (92.6) 0.44d
    Positive 7 (4.8) 9 (7.4)
Self-reported STDe
    No 138 (91.4) 115 (92.7) 0.82d
    Yes 13 (8.6) 9 (7.3)
NOTE. VIA: visual inspection with acetic acid; HPV: human papillomavirus; HSV-2: herpes virus type 2
a
Percentages do not include missing values
b
P-value comparing the intervention vs. control groups at baseline Pearson’s chi-square test unless otherwise noted.
c




Sexually transmitted disease (current or within the last 6 months)
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